177 related articles for article (PubMed ID: 24766821)
1. Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab.
Ara M; Pastushenko E
Actas Dermosifiliogr; 2014 Dec; 105(10):900-12. PubMed ID: 24766821
[TBL] [Abstract][Full Text] [Related]
2. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
3. [Cutaneous side effects of antiangiogenic agents].
Robert C
Bull Cancer; 2007 Jul; 94 Spec No():S260-4. PubMed ID: 17846013
[TBL] [Abstract][Full Text] [Related]
4. [Dermatologic side effects induced by new angiogenesis inhibitors].
Sibaud V; Garrido-Stowhas I; Cottura E; Chevreau C
Bull Cancer; 2011 Oct; 98(10):1221-9. PubMed ID: 22001771
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
Oh WK; McDermott D; Porta C; Levy A; Elaidi R; Scotte F; Hawkins R; Castellano D; Bellmunt J; Rha SY; Sun JM; Nathan P; Feinberg BA; Scott J; McDermott R; Ahn JH; Wagstaff J; Chang YH; Ou YC; Donnellan P; Huang CY; McCaffrey J; Chiang PH; Chuang CK; Korves C; Neary MP; Diaz JR; Mehmud F; Duh MS
Int J Oncol; 2014 Jan; 44(1):5-16. PubMed ID: 24247547
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
McLellan B; Kerr H
Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
[TBL] [Abstract][Full Text] [Related]
8. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
9. Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions.
Koldenhof JJ; Witteveen PO; de Vos R; Walraven M; Tillier CN; Verheul HM; Teunissen SC
Support Care Cancer; 2014 Sep; 22(9):2371-80. PubMed ID: 24687539
[TBL] [Abstract][Full Text] [Related]
10. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
Alasker A; Meskawi M; Sun M; Ismail S; Hanna N; Hansen J; Tian Z; Bianchi M; Perrotte P; Karakiewicz PI
Cancer Treat Rev; 2013 Jun; 39(4):388-401. PubMed ID: 23317510
[TBL] [Abstract][Full Text] [Related]
11. [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
Fléchon A; Boyle H; Négrier S
Bull Cancer; 2010; 97():73-82. PubMed ID: 20418206
[TBL] [Abstract][Full Text] [Related]
12. Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Herbst RS
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S23-30. PubMed ID: 17239287
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure.
Westgeest HM; van Erp NP; Honeywell RJ; Hoekstra R; Peters GJ; Verheul HM
J Clin Oncol; 2013 Feb; 31(6):e83-6. PubMed ID: 23182994
[No Abstract] [Full Text] [Related]
14. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
Girardi F; Franceschi E; Brandes AA
Oncologist; 2010; 15(7):683-94. PubMed ID: 20547589
[TBL] [Abstract][Full Text] [Related]
15. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
Nardone B; Hensley JR; Kulik L; West DP; Mulcahy M; Rademaker A; Lacouture ME
J Drugs Dermatol; 2012 Nov; 11(11):e61-5. PubMed ID: 23135095
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
[TBL] [Abstract][Full Text] [Related]
17. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Lipworth AD; Robert C; Zhu AX
Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.
Walraven M; Witteveen PO; Lolkema MP; van Hillegersberg R; Voest EE; Verheul HM
Angiogenesis; 2011 May; 14(2):135-41. PubMed ID: 21188500
[TBL] [Abstract][Full Text] [Related]
19. [Hand-foot syndrome after administration of tyrosinkinase inhibitors].
Bednaríková D; Kocák I
Klin Onkol; 2010; 23(5):300-5. PubMed ID: 21061680
[TBL] [Abstract][Full Text] [Related]
20. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
